Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 6, 2026

Mobileye To Acquire Mentee Robotics to Accelerate Physical AI Leadership

View original at finance.yahoo.com
Mobileye To Acquire Mentee Robotics to Accelerate Physical AI Leadership Mobileye and Mentee RoboticsMentee Robotics is developing an AI-first, vertically integrated humanoid robot designed for real-world usefulness and adaptability.MenteeBot showcases the complete autonomous execution of a task, encompassing scene per…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Joining forces with Mobileye gives access to unparalleled AI infrastructure and commercialization expertise, accelerating mission to bring scalable, safe, and cost-effective humanoid solutions to market

    80% confidence

  • Mentee's multidisciplinary team accomplished building a platform that combines cutting-edge AI with deeply integrated hardware to make humanoid robots truly useful in real-world environments in just four years

    80% confidence

  • Strong traction in advanced vehicle autonomy and core ADAS technology has resulted in current automotive revenue pipeline of $24.5 billion over next eight years, up more than 40 percent compared to January 2023

    80% confidence

  • By combining Mentee's breakthroughs in humanoid robotics with Mobileye's expertise in automotive autonomy, and its proven ability to productize advanced AI, we have a unique opportunity to lead the evolution of physical AI across robotics and autonomous vehicles on a global scale

    80% confidence

  • Today marks a new chapter for robotics and automotive AI, and the beginning of Mobileye 3.0

    80% confidence

  • Transaction expected to modestly increase Mobileye's operating expenses in 2026 by a low-single-digit percentage

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com